Clinical trial · Interventional
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736CI-TRIAL-00085752recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CXCR4-related Disease | — | UNRESOLVED | — |
| Metastasis | — | UNRESOLVED | — |
| Positron Emission Tomography | — | UNRESOLVED | — |
| Tumor | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CXCR4 PET/CT Imaging | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CXCR4 PET/CT Imaging
- description
- Intravenous injection of one dose of 2-5 mCi 68Ga/18F-Pentixafor/Pentixather. Tracer doses of radiotracers will be used to image lesions by PET/CT
- interventionNames
- Diagnostic Test: CXCR4 PET/CT Imaging
Primary outcomes (1)
- measure
- Standardized uptake value (SUV)
- timeFrame
- 30 days
- description
- Standardized uptake value (SUV) of FAPI for each target lesion of subject or suspected primary tumor or/and metastasis.
Secondary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor
References
Publications (0)
Data not yet available
No reference posted for this study.